Stock of Immune Response Corp. has picked up $5.38 sincebiotech analyst Mark Simon of Robertson, Stephens & Co.published a report on Friday reiterating his aggressive "buy" onthe San Diego company's stock. The stock (NASDAQ:IMNR)closed up $2.88 on Monday at $22.38.
Simon, who has had a strong buy on the stock since April, set atarget price of $24 within the next nine to 12 months.
Immune Response has a vaccine based on the inactivated coreof the HIV virus in Phase II/III clinical trials.
(c) 1997 American Health Consultants. All rights reserved.